STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Feb. 28, 2013	Feb. 29, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,498,806)	$ (7,157,662)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation	683	701
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph. D.	5,640,314	6,663,784
Warrants issued for services	159,896
Change in operating assets and liabilities
Accounts payable	35,236	(26,958)
Accrued liabilities	(8,610)	16,071
NET CASH USED IN OPERATING ACTIVITIES	(671,287)	(504,064)
CASH FLOWS FROM FINANCING ACTIVITIES
Cash contribution recorded	655,182	503,885
NET CASH PROVIDED BY FINANCING ACTIVITIES	655,182	503,885
NET DECREASE IN CASH	(16,105)	(179)
CASH AT BEGINNING OF YEAR	17,297	17,476
CASH AT END OF YEAR	1,192	17,297
Cash Paid During the Year For:
Taxes	$ 0	$ 0